Metropolis Healthcare Reports Strong Q4 FY26 Performance with 23% Revenue Growth
Metropolis Healthcare Ltd. announced a business update for the quarter ended March 31, 2026, reporting significant revenue growth driven by continued traction in its TruHealth wellness and specialized testing segments. The company’s consolidated revenues increased by approximately 23% on a year-on-year basis.The business performance was supported by growth across both business-to-consumer (B2C) and business-to-business (B2B) channels. B2C revenue grew by approximately 19% while B2B revenue increased by approximately 30% on a year-on-year basis. The TruHealth Wellness and Specialty segments recorded growth of approximately 25% and 29%, respectively, in the fourth quarter of fiscal year 2026.
Key Financial Highlights for Q4 FY26 (MHL Group):
| Metric | Growth (Year-on-Year) |
|---|---|
| Revenue | ~23% |
| B2C Revenue | ~19% |
| B2B Revenue | ~30% |
| TruHealth Wellness Segment Revenue | ~25% |
| Specialty Segment Revenue | ~29% |
The company noted that acquisitions completed in the prior year are progressing well, with integration efforts and synergy benefits contributing to positive outcomes. Margin in Core Diagnostics is improving, currently in the high single-digit range. Additionally, DAPIC, Scientific, and Ambika continue to deliver margins above the company's average.
Q4 FY26 (MHL Organic):
Revenue grew by approximately 14.5% year-on-year, attributable to increased patient and test volume alongside product mix improvements. EBITDA margins also improved year-on-year, driven by operating leverage and efficiency gains.
*MHL Organic excludes recent acquisitions of Core Diagnostics, DAPIC, Scientific, and Ambika.
The quarterly business update is based on a consolidated basis. The financial results for Q4 FY26 are still subject to audit.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.